CD4+CD25+ immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade

被引:460
作者
Taylor, PA
Noelle, RJ
Blazar, BR
机构
[1] Univ Minnesota, Ctr Canc, Dept Pediat, BMT Div, Minneapolis, MN 55455 USA
[2] Dartmouth Med Coll, Dept Microbiol, Lebanon, NH 03756 USA
关键词
regulatory T cell; IL-2 receptor alpha chain (CD25); tolerance; transplantation; in vivo animal models;
D O I
10.1084/jem.193.11.1311
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Immune regulatory CD4(+)CD25(+) cells play a vital role in the induction and maintenance of self-tolerance and are essential for T cell homeostasis and the prevention of autoimmunity. Induction of tolerance to allogeneic donor grafts is a clinically desirable goal in bone marrow and solid organ transplantation To determine whether CD4(+)CD25(+) cells regulate T cell responses to alloantigen and are critical for tolerance induction, murine CD4(+) T cells were tolerized to alloantigen via ex vivo CD40 ligand (CD40L)/CD40 or CD28/cytotoxic T lymphocyte-associated antigen 4/B7 blockade resulting in secondary mixed leukocyte reaction hyporesponsiveness and tolerance to alloantigen in vivo. CD4(+)CD25(+) T cells were found to be potent regulators of alloresponses. Depletion of CD4(+)CD25(+) T cells from the CD4(+) responder population completely abrogated ex vivo tolerance induction to alloantigen as measured by intact responses to alloantigen restimulation in vitro and in vivo. Addback of CD4(+)CD25(+) T cells to CD4(+)CD25(-) cultures restored tolerance induction. These data are the first to indicate that CD4(+)CD25(+) cells are essential for the induction of tolerance to alloantigen and have important implications for tolerance-inducing strategies targeted at T cell costimulatory pathways.
引用
收藏
页码:1311 / 1317
页数:7
相关论文
共 29 条
  • [1] Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation
    Asano, M
    Toda, M
    Sakaguchi, N
    Sakaguchi, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) : 387 - 396
  • [2] Blazar BR, 1997, J IMMUNOL, V158, P29
  • [3] CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses
    Blazar, BR
    Taylor, PA
    Noelle, RJ
    Vallera, DA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (03) : 473 - 482
  • [4] BONOMO A, 1995, J IMMUNOL, V154, P6602
  • [5] Cederbom L, 2000, EUR J IMMUNOL, V30, P1538, DOI 10.1002/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO
  • [6] 2-X
  • [7] Cutting edge: Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning
    Durham, MM
    Bingaman, AW
    Adams, AB
    Ha, JW
    Waitze, SY
    Pearson, TC
    Larsen, CP
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 165 (01) : 1 - 4
  • [8] CTLA4-Ig and anti-CD4O ligand prevent renal allograft rejection in primates
    Kirk, AD
    Harlan, DM
    Armstrong, NN
    Davis, TA
    Dong, YC
    Gray, GS
    Hong, XN
    Thomas, D
    Fechner, JH
    Knechtle, SJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (16) : 8789 - 8794
  • [9] Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
    Kirk, AD
    Burkly, LC
    Batty, DS
    Baumgartner, RE
    Berning, JD
    Buchanan, K
    Fechner, JH
    Germond, RL
    Kampen, RL
    Patterson, NB
    Swanson, SJ
    Tadaki, DK
    TenHoor, CN
    White, L
    Knechtle, SJ
    Harlan, DM
    [J]. NATURE MEDICINE, 1999, 5 (06) : 686 - 693
  • [10] SURVIVAL OF MOUSE PANCREATIC-ISLET ALLOGRAFTS IN RECIPIENTS TREATED WITH ALLOGENEIC SMALL LYMPHOCYTES AND ANTIBODY TO CD40 LIGAND
    PARKER, DC
    GREINER, DL
    PHILLIPS, NE
    APPEL, MC
    STEELE, AW
    DURIE, FH
    NOELLE, RJ
    MORDES, JP
    ROSSINI, AA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (21) : 9560 - 9564